Krónikus vesebetegség: vizsgálatok itt: Németország
35 of 43 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 18.. Ask the study team whether a trial fits you.
- 3. fázisNot yet taking people in NémetországA Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease Treated With Once Daily Basal Insulin Alone or in Combination With Metformin, SGLT2i, or Both
- Where
- Bad Mergentheim, Berlin, Ludwigshafen, Mainz, Münster, Pirna, Pohlheim
- Életkor
- 18 év and over
- People
- 450 worldwide
- Run by
- Novo Nordisk A/S
See details and how to joinNCT07931547 · EU 2026-525471-13-00 - 1. fázisTaking peopleSafety, Tolerability, Pharmacokinetics and Pharmacodynamics of OJR520 in Healthy Volunteers and Participants With Chronic Kidney Disease
- Where
- Berlin
- Életkor
- 18 év to 65 év
- People
- 112 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07235059 - 3. fázisTaking peopleA Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
- Where
- Bad Homburg, Bamberg, Berlin, Bochum, Brandenburg an der Havel, Brandenburg An Der Havel, Dresden, Essen, Goerlitz, Goettingen, Hanover, Heidelberg, Herne, Karlsburg, Karlsruhe, Landshut, Mainz, Obertshausen, Offenbach Am Main, Potsdam, Reinfeld, Rostock, Rotenburg, Ulm, Wermsdorf, Zwenkau
- Életkor
- 18 év and over
- People
- 5000 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06742723 · EU 2023-506460-14-00 - No phaseTaking peopleImpact of Propionic Acid on Regulatory T Cell Function in Children With CKD
- Where
- Berlin
- Életkor
- 12 év to 20 év
- People
- 16
- Run by
- Charite University, Berlin, Germany
See details and how to joinNCT05858437 - 3. fázisTaking peopleA Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
- Where
- Essen, Essen, Ruhr, Goch, Hamburg, Köln, Oldenburg in Holstein, Stuhr
- Életkor
- 50 év and over
- People
- 7140 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07241390 · EU 2025-523123-22-00 - 1. fázisNot yet taking people in NémetországA study to learn how safe nurandociguat is when taken with sildenafil in men with arterial hypertension.
- Where
- Berlin, Mannheim
- Életkor
- 18 év to 64 év
- People
- 36
- Run by
- Bayer AG
See details and how to join2025-522336-14-00 - No phaseTaking peopleSPYRAL GEMINI Pilot Study
- Where
- Erlangen, Homburg
- Életkor
- 18 év to 80 év
- People
- 175 worldwide
- Run by
- Medtronic Vascular
See details and how to joinNCT06907147 - 3. fázisTaking peoplePhase 3 Clinical Trial With Dapagliflozin in Chronic Kidney Disease in Adolescents and Young Adult Patients
- Where
- Berlin, Cologne, Frankfurt am Main, Göttingen, Hamburg, Heidelberg, Leipzig, München, Münster
- Életkor
- 10 év to 39 év
- People
- 102
- Run by
- University Hospital Goettingen
See details and how to joinNCT05944016 · EU 2023-508502-18-00 - No phaseTaking peopleStreamlined Denervation With spYral For an Optimized Treatment (SPYRAL SWYFT) in Subjects With Uncontrolled Hypertension
- Where
- Erlangen, Homburg, Leipzig, Lübeck, Villingen-Schwenningen
- Életkor
- 18 év and over
- People
- 130 worldwide
- Run by
- Medtronic Vascular
See details and how to joinNCT07115953 - 2. fázisTaking peopleDose-finding Study of YMI024 to Assess Efficacy, Safety, and Tolerability in Adults With Stable Coronary Artery Disease and Elevated hsCRP
- Where
- Berlin, Essen, Freiburg im Breisgau, Gladbeck, Kaiserslautern, Konstanz, Leipzig, Loehne, Ludwigshafen, Mannheim, Pirna, Stuttgart, Ulm
- Életkor
- 18 év to 80 év
- People
- 180 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07830719 · EU 2026-525974-21-00 - 4. fázisTaking peopleCKD-bioMatch: A biomarker-targeted clinical trial to optimize treatment for patients with chronic kidney disease
- Where
- Hamburg
- Életkor
- 18 év and over
- People
- 115 worldwide
- Run by
- Steno Diabetes Center Copenhagen
See details and how to join2023-507449-27-01 - 1. fázisNot yet taking people in NémetországA Study to Learn About How Safe Nitroglycerin is and How it Affects the Body When Taken Along With Nurandociguat in People With Coronary Artery Disease
- Where
- Berlin, Bonn, Erfurt, Heidelberg
- Életkor
- 40 év to 80 év
- People
- 36 worldwide
- Run by
- Bayer
See details and how to joinNCT07431294 · EU 2025-522335-34-00 - 3. fázisFut, nem toborozA Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
- Where
- Aachen, Berlin, Dresden, Essen, Freiburg im Breisgau, Hanover, Kiel, Magdeburg, Mainz, Stuttgart, Tuebingen, Ulm
- Életkor
- 18 év to 100 év
- People
- 540 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT04557462 · EU 2023-508690-92-00 - 3. fázisFut, nem toborozA Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria
- Where
- Berlin, Bonn, Essen, Hamburg, Hanover, Heidelberg, Muenster
- Életkor
- 1 év to 18 év
- People
- 100 worldwide
- Run by
- Bayer
See details and how to joinNCT05457283 · EU 2023-504885-50-00 - 3. fázisNot yet taking people in NémetországA Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD)
- Where
- Aachen, Bad Nenndorf, Berlin, Bonn, Brandenburg an der Havel, Braunschweig, Cloppenburg, Essen, Frankfurt am Main, Fulda, Gladbeck, Goslar, Hanover, Heidelberg, Leipzig, Magdeburg, München, Münster, Nuremberg, Obertshausen, Riesa, Rostock, Rotenburg (Wümme), Villingen-Schwenningen, Würzburg
- Életkor
- 18 év to 99 év
- People
- 2800 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07624305 · EU 2026-526114-90-00 - 2. fázisTaking peopleEfficacy and Safety of SP16 in Preventing Acute Kidney Injury in At-risk Subjects With Chronic Kidney Disease Undergoing Elective Cardiac Surgery Using the Heart-lung-machine
- Where
- Erlangen
- Életkor
- 18 év and over
- People
- 120
- Run by
- University of Erlangen-Nürnberg Medical School
See details and how to joinNCT07661940 · EU 2025-522491-89-00 - 2/3. fázisTaking peopleCombined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
- Where
- Berlin, Hessen, Kaiserslautern, Kiel, Leipzig, Mainz, Villingen-Schwenningen
- Életkor
- 18 év and over
- People
- 3110 worldwide
- Run by
- CSL Behring
See details and how to joinNCT05485961 · EU 2022-500273-14-00 - 3. fázisTaking peopleA Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.
- Where
- Aachen, Ahrensburg, Bad Mergentheim, Bad Nenndorf, Bamberg, Berlin, Brandenburg An Der Havel, Brunswick, Chemnitz, Cloppenburg, Dortmund, Dresden, Duesseldorf, Duisburg, Erlangen, Essen, Frankfurt am Main, Freiburg, Fulda, Gladbeck, Goettingen, Goslar, Hamburg, Hanover, Heidelberg, Herne, Kiel, Landshut, Leipzig, Luebeck, Magdeburg, Mannheim, München, Munich, Nuremberg, Reinfeld, Riesa, Rostock, Rotenburg, Stuttgart, Trier, Ulm, Wiesbaden, Wuerzburg
- Életkor
- 18 év and over
- People
- 7000 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07753993 · EU 2025-523994-41-00 - 1. fázisNot yet taking people in NémetországA Research Study Looking Into How a Single Dose of the Medicine NNC0537-1482 Moves Through the Body of Participants With Normal or Reduced Kidney Function
- Where
- Berlin
- Életkor
- 18 év to 75 év
- People
- 54
- Run by
- Novo Nordisk A/S
See details and how to joinNCT07808788 - 3. fázisTaking peopleA Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin
- Where
- Bad Oeynhausen, Berlin, Chemnitz, Duisburg, Erlangen, Frankfurt am Main, Hamburg, Heilbronn, Hohenmölsen, Ludwigshafen, Münster, Nittendorf, Obertshausen, Pirna, St Ingbert, Stuttgart
- Életkor
- 18 év and over
- People
- 900 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07662135 · EU 2025-523940-12-00 - 3. fázisTaking peopleA Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis
- Where
- Cologne, Hamburg, Heidelberg
- Életkor
- 2 év to 17 év
- People
- 24 worldwide
- Run by
- Amgen
See details and how to joinNCT03969329 · EU 2023-506471-10-00 - 1. fázisNot yet taking people in NémetországA Participant- and Investigator--Blinded, Placebo-Controlled, Randomized, Multipart, Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of OJR520 in Healthy Volunteers and Participants with Chronic Kidney Disease
- Where
- Berlin
- Életkor
- 18 év and over
- People
- 44 worldwide
- Run by
- Novartis Pharma AG
See details and how to join2025-520978-18-00 - 2. fázisTaking peopleAlbuminuria Reduction Trial and Investigation with Survodutide Treatment in CKD (ARTIST-CKD)
- Where
- Erlangen, Karlsruhe, Stuttgart
- Életkor
- 18 év and over
- People
- 95 worldwide
- Run by
- Universitair Medisch Centrum Groningen
See details and how to join2025-525068-13-00 - 4. fázisTaking peopleDapagliflozin on Renal Morphology and Renal Perfusion in Patients One Year After Kidney Transplantation
- Where
- Erlangen
- Életkor
- 18 év to 75 év
- People
- 48
- Run by
- University of Erlangen-Nürnberg Medical School
See details and how to joinNCT06560801 - 3. fázisTaking peopleEfficacy and Safety of XyloCore Peritoneal Dialysis Solution.
- Where
- Düsseldorf
- Életkor
- 18 év and over
- People
- 170 worldwide
- Run by
- Iperboreal Pharma Srl
See details and how to joinNCT03994471